Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,878.38 -2,012.10 (-3.20%) CMC Crypto 200
1,260.36 -97.65 (-7.19%)
ASLAN Pharmaceuticals Limited (ASLN)
After hours:
| Previous close | 0.4198 |
| Open | 0.4200 |
| Bid | 0.4152 x 100 |
| Ask | 0.4270 x 100 |
| Day's range | 0.4100 - 0.4345 |
| 52-week range | 0.3920 - 4.6900 |
| Volume | |
| Avg. volume | 1,249,806 |
| Market cap | 9.61M |
| Beta (5Y monthly) | 1.52 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.7500 |
| Earnings date | 09 Aug 2024 - 13 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.50 |
GlobeNewswireASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Positive interim data readout from 22 patients in TREK-DX study of eblasakimab showed unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 (at least a 90% reduction in their Eczema Area Severity Index (EASI) score) and 66.7% achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks, versus 14.3% of patients on placebo. On track to report topl
- GlobeNewswire
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
New positive data from an additional analysis of dupilumab-experienced patients treated with eblasakimab 400mg, weekly over 16 weeks further support the recent finding that some AD patients may respond to eblasakimab even after having an inadequate response to dupilumabData to be presented in a KOL event to be held Tuesday, May 7, 2024 at 8:00 am ET, register here SAN MATEO, Calif. and SINGAPORE, May 07, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-
- GlobeNewswire
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab and lebrikizumab.The findings will deepen understanding of the biology underlying the recent finding that some AD patients may respond to eblasakimab even after having an inadequate response to dupilumab.The first part of the collaboration will focus on receptor biology and kinetics to investigate the cellular and molecular basis of ebla
